Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to find the safest dose level of an approved drug, carfilzomib, in solid tumors when given over a different period of time than normally used. The study will also use markers in blood from routine blood draws to help check the levels of the drug. Lastly, the study will check how well this drug works with regards to keeping cancer cells from growing with the new time frame of delivery.


Clinical Trial Description

The role of the proteasome in carcinogenesis and cell survival has been well established, and its inhibition associated with an accumulation of pro-apoptotic proteins and cell death. Proteasome inhibitors, such has bortezomib, have been extensively studied and are widely used as effective therapy in the treatment for hematologic malignancies, such as multiple myeloma where circulating proteasome levels have been correlated with survival. Carfilzomib, a novel irreversible proteasome inhibitor which specifically targets the chymotryptic site of the proteasome has shown more potency than bortezomib and may be able to overcome bortezomib resistance. Response rates between 25-54% were seen in patients with previously treated myeloma in the phase 2 setting.

Given the effectiveness of proteasome inhibition in multiple myeloma, the role of proteasome in solid tumors is under active investigation. Previous trials of bortezomib in breast, prostate, lung, and pancreatic cancer have shown little activity of this agent in these diseases. Whether the lack of activity may be mechanistically related (bortezomib inhibits chymotrypsin-like and peptidyl-glutamyl peptide-hydrolyzing (PGPH)-like activities of the proteasome), or a lack of potency in target inhibition, is unknown.

In a phase Ib/II study of 14 patients (phase I) and 51 patients (phase II) with advanced solid tumors, Rosen and colleagues noted single-agent activity with carfilzomib. Carfilzomib was dosed on days 1, 2, 8, 9, 15, and 16 of a 28 day cycle to a maximum of 12 cycles, with 20-36 mg/m² noted as the recommended phase 2 dose based on DLT data. A PR in both renal and small cell lung cancer, and stable disease > 16 weeks in mesothelioma, ovarian, renal, and non-small cell lung cancer was observed. The treatment was tolerable with the most common adverse events (AEs) including fatigue, headache, diarrhea, nausea and constipation.

Given the activity of carfilzomib seen in selected solid tumors, and unpublished data to suggest weekly dosing may result in a similar pharmacokinetic profile including AUC, the investigators propose to study the safety, tolerability, pharmacokinetics, and anti-tumor activity of carfilzomib monotherapy given on a weekly dosing schedule. Weekly dosing has the advantage of patient convenience, and if acceptable toxicity and pharmacokinetics, it allows for easier integration of this schedule into subsequent combination therapy clinical trials. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02257476
Study type Interventional
Source Emory University
Contact
Status Completed
Phase Phase 1
Start date August 2014
Completion date November 2016

See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2